en · de · es · fr · pt
sr9009-notes.peptides3626.com › Wiki › Background And Mechanism — Background and Details

Background And Mechanism — Background and Details

By Editorial Desk · published 2025-08-17 · last reviewed 2025-10-02 · Wiki

Everything below concerns NR1D2. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-10-02. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

SR9009 Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SDerived from published structure.
Molecular weight437.94 g/molCalculated value.
AppearanceWhite to off-white solidTypical for purified research samples.
SolubilityDMSO, ethanol; low in waterClass: poorly water-soluble.
Typical storage-20 °C, desiccated, protected from lightLimits degradation.

Background and Mechanism of SR9009

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

Related pages on this site

Mechanism and Preclinical Findings

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

Supporting material

Archives of Biochemistry and Biophysics is a biweekly peer-reviewed scientific journal that covers research in biochemistry and biophysics. It is published by Elsevier. As of 2012, the editors-in-chief were Paul Fitzpatrick (University of Texas Health Science Center at San Antonio), Helmut Sies (University of Düsseldorf), Jian-Ping Jin (Wayne State University School of Medicine), and Henry Jay Forman (University of Southern California). The journal was established in 1942 by Academic Press as the Archives of Biochemistry, obtaining its current name in 1952. It absorbed the journal Molecular Cell Biology Research Communications (formerly section B of Biochemical and Biophysical Research Communications), which was published from 1999 to 2001. An index to authors for the first 75 volumes, covering the period from 1943 to 1958, was published in October 1959.

Most atomic nuclei contain protons and neutrons. The number of protons determines the chemical element the nucleus belongs to. Different isotopes of the same element have different numbers of neutrons in their nuclei, but contain the same number of protons. For example, isotopes of carbon include carbon-12, carbon-13, carbon-14, which contain 6, 7, 8 neutrons respectively, but all contain 6 protons. Each isotope of an element has a different nuclear energy state, and may have different stability.

== Health risks == The biological behaviour of caesium is similar to that of potassium‍ and rubidium. After entering the body, caesium gets more or less uniformly distributed throughout the body, with the highest concentrations in soft tissue.‍ However, unlike group 2 radionuclides like radium and strontium-90, caesium does not bioaccumulate and is excreted relatively quickly. The biological half-life of caesium is about 70 days.‍ It has been demonstrated that pancreatic tissue is a strong accumulator and secretor in the intestine of radioactive caesium (137Cs). A 1961 experiment showed that mice dosed with 21.5 μCi/g of 137Cs had a 50% fatality rate within 30 days, implying an LD50 of 245 μg/kg.‍ A similar experiment in 1972 showed that when dogs are subjected to a whole body burden of 3800 μCi/g (140 MBq/kg, or approximately 44 μg/kg) of caesium-137 (and 950 to 1400 rad), they die within 33 days, while animals with half of that burden all survived for a year.‍ A 1960 mouse study found there were high levels of 137Cs for the first day after exposure in the mucus glands of the colon, the pancreas, cartilage, tendons, and skeletal muscle. After 24 hours, cartilage and skeletal muscle showed the highest activity.‍ In 2003, a study found that children from the 137Cs-polluted area in Belarus near Chernobyl suffered from chronic diseases rarely found in children in other areas of Belarus.

Sources: en.wikipedia.org

Supporting material

=== Muscle stimulation === In 1856 Guillaume Duchenne announced that alternating was superior to direct current for electrotherapeutic triggering of muscle contractions. What he called the 'warming effect' of direct currents irritated the skin, since, at voltage strengths needed for muscle contractions, they cause the skin to blister (at the anode) and pit (at the cathode). Furthermore, with DC each contraction required the current to be stopped and restarted. Moreover, alternating current could produce strong muscle contractions regardless of the condition of the muscle, whereas DC-induced contractions were strong if the muscle was strong, and weak if the muscle was weak. Since that time almost all rehabilitation involving muscle contraction has been done with a symmetrical rectangular biphasic waveform. During the 1940s, however, the U.S. War Department, investigating the application of electrical stimulation not just to retard and prevent atrophy but to restore muscle mass and strength, employed what was termed galvanic exercise on the atrophied hands of patients who had an ulnar nerve lesion from surgery upon a wound. These galvanic exercises employed a monophasic (single-pulse) direct current waveform. The American Physical Therapy Association, a professional organization representing physical therapists, accepts the use of electrotherapy in the field of physical therapy.

=== Later === Many protest songs during the 1980s reflected general unease with escalating tensions between the Soviet Union and the United States brought on by Ronald Reagan's and Margaret Thatcher's hard line against the Soviets. For example, various musical artists wore military uniform-like costumes, as a reflection of the increased feeling of militarism seen in the 1980s. Songs symbolically showed the superpowers going to war, as in the Frankie Goes to Hollywood song "Two Tribes". This song's MTV music video featured caricatures of United States President Ronald Reagan and Soviet General Secretary Konstantin Chernenko in a wrestling match. Other songs expressed fear of World War III, as in the Sting song, "Russians", with lyrics such as "I don't subscribe to his [Reagan's or Khrushchev's] point of view" (that Reagan would protect Europe, or that Khrushchev would "bury" the West). Other examples include Sly Fox's "Let's go all the way", a song about "going all the way" to nuclear war, The Escape Club's "Wild, Wild West" with its various references to the Cold War and Fischer-Z's album "Red Skies over Paradise". The Genesis song "Land of Confusion" expressed a desire to make some sense out of the world, especially in relation to nuclear war. A number of punk rock bands from the 1980s attacked Cold War era politics, such as Reagan's and Thatcher's nuclear deterrence brinkmanship. A small sampling includes The Clash, Dead Kennedys, Government Issue, Fear, Suicidal Tendencies, Toxic Reasons, Reagan Youth, etc. Noted punk compilation P.E.A.C.E.

=== Electrical conductivity and electrolysis === Pure water has a low electrical conductivity, which increases with the dissolution of a small amount of ionic material such as common salt. Liquid water can be split into the elements hydrogen and oxygen by passing an electric current through it—a process called electrolysis. The decomposition requires more energy input than the heat released by the inverse process (285.8 kJ/mol, or 15.9 MJ/kg).

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Is SR9009 a SARM?

No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.

Are there human trials of SR9009?

Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.

What is SR9009?

It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.

Network